Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ENLV with free AI briefings, catalyst countdowns, and dilution alerts.

ENLV · Enlivex Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.5M Cash on Hand
4.3mo Cash Runway
Follow ENLV by email Get an email when ENLV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ENLV, unsubscribe in one click. Privacy

📣 What ENLV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allocetra Primary Knee Osteoarthritis Phase 2 · NCT07580716 Recruiting
Allogeneic Ex-vivo-treated Peripheral Blood… Sepsis Phase 2 · NCT04612413 Completed

Also used in these trials (approved or third-party drugs, not ENLV's own candidates): Nivolumab, Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ENLV holds $5.5M in cash and short-term investments and burns about $3.9M/quarter from operations, an estimated runway of 4.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENLV files for a raise →

👥 Who Owns ENLV

Insiders 3.2% Other 5%+ holders 0.8% Institutions (21 holders) 1.4% Public and other holders 94.6%
HolderTypeShares% of sharesAs of
Shai A Novik
Director
Insider 6,974,017 2.94% 2026-03-18
Lind Global Asset Management XIV, LLC 5%+ holder (13G) 1,927,744 0.81% 2026-08-11
Avraham Havron
Director
Insider 183,836 0.08% 2026-03-18
Oren Hershkovitz
Chief Executive Officer
Insider 172,855 0.07% 2026-03-18
Einat Galamidi
Chief Medical Officer
Insider 156,304 0.07% 2026-03-18
Shachar Shlosberger
Chief Financial Officer
Insider 139,314 0.06% 2026-03-18
Gili Hart
Director
Insider 7,672 0.00% 2026-03-18
Roger Pomerantz
Director
Insider 2,480 0.00% 2026-03-18

Share count 237,381,498 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ENLV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENLV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.